BioOutsource collaborates with Glythera on ADC characterization

Scotland-based BioOutsource has amplified its position in antibody drug conjugates (ADC) characterisation through a partnership with UK emerging biotech firm Glythera that specializes in the development of next-generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.

“Building on our position as a leader in biological characterization of monoclonal antibodies, ADC’s represent an exciting development which will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterize their ADC product in development, as we believe it holds considerable promise,” commented BioOutsource’s chief scientific officer Daniel Galbraith.

Glythera chief operating officer David Simpson highlighted the value of the collaboration, saying: “We are delighted to have the opportunity to work with BioOutsource on their ADC characterization as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”